Flu A/B & SARS-CoV-2 Detection Kit
Intended use:
Suspected qualitative RNA detection of SARS-CoV-2 (2019-nCoV) and Influenza A / B in samples from individuals suspected of COVID-19 by your healthcare provider.
High performance:
With the rapid spread of COVID-19, conventional nucleic manual Acid extraction can hardly stand a rapid
high-performance tests.
The Andis 350 Automated Nucleic Acid ANDiS SARS-CoV-2 extraction system and influenza A / B RT-qPCR detection kit
Increase daily performance 5 to 25 times.
Differential diagnosis:
From COVID-19 Symptoms can easily be confused with other respiratory infections, diagnoses are urgently needed to distinguish SARS-CoV-2 influenza A / B virus.
- Multiple targets: designed to minimize erroneous detection.
- Inclusion of influenza A / B: as objectives to facilitate differentiation between COVID-19 and Flu A / B.
- No cross-reaction: with SARS-CoV or MERS-CoV
The Impact
1. Multi-target: in order to minimize false calls, primers and probes are designed to simultaneously, target specific sequences of SARS-CoV-2 (ORF1ab and N gene), Flu A (M gene), and FluB (NP gene) in a signal assay.
2. LoD = 5 copies/reaction: SARS-CoV-2 could be present with very low viral titers in some samples, especially those obtained from patients with early infection. A virus detection assay with high Sensitivity can significantly reduce false negatives.
3. Real-world clinical evaluation: RNA samples extracted from 282 clinical samples were submitted for SARS-CoV-2 testing using Next Generation Sequencing (NGS) and ANDiS SARS-CoV-2 and the influenza A / B RT-qPCR detection kit. The performance of the kit was evaluated against NGS.
4. Inclusivity and specificity: the test covers 100% of the known SARS-CoV-2 sequences based on the NCBI & GISAID database as of February 20, 2020. No cross-reactions were observed with other pathogens commonly found in respiratory specimens.
5. Multiple Controls – One positive control and one negative control are included in each run to ensure that the assay is working properly and to identify possible reagent contamination, respectively. Internal control is included in each reaction to monitor the reverse transcription and PCR amplification.
Workflow
The Andis SARS-CoV-2 and Influenza A / B RT-qPCR detection kit are recommended for use in conjunction with the Andis 350 Automated Nucleic Acid Extraction System (or QIAamp DSP Viral RNA Mini Kit) and the ABI 7500 real-time PCR instrument. Otherwise, a real-time PCR instrument capable of detecting FAM, ROX, VIC, CY5 and TAMRA is required.
Technology
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
Components
- RT-qPCR reaction mix
- Enzyme blend
- SARS-CoV-2 test
- Influenza A / B Assay
- Positive Control, Negative Control and Internal Control
Required materials (not included)
- RNA extraction and purification
- ANDiS350 Automated Nucleic Acid Extraction System (Instrument + Reagents)
- Or QIAamp DSP viral RNA mini kit
- ABI 7500 real-time PCR system (or equivalent)
- Other laboratory supplies for molecular testing
- Personal protection equipment
